Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral, direct-acting, and reversible P2Y$_{12}$ platelet inhibitor. It belongs to the cyclopentyltriazolopyrimidine (CPTP) class.
## Primary Indications
* **Acute Coronary Syndrome (ACS):** To reduce the rate of cardiovascular events, including cardiovascular death, myocardial infarction (MI), and stroke, in patients with ACS.
* **History of MI:** For the prevention of thrombotic events in patients with a history of MI and high risk for an additional atherothrombotic event.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* **History of MI:**
* **Maintenance Dose:** 60 mg orally twice daily.
## Pediatric Dosing
* There is no established pediatric dosing for ticagrelor. Its use in pediatric populations is not generally recommended.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is recommended in patients with mild to moderate hepatic impairment. Ticagrelor is not recommended in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is needed for mild, moderate, or severe renal impairment.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Most Common:** Dyspnea, bradycardia, atrial fibrillation, bleeding (including fatal and life-threatening bleeding).
* **Serious:** Major bleeding, intracranial hemorrhage, ventricular pauses, hypersensitivity reactions.
## Key Drug Interactions
* **CYP3A4 Substrates (e.g., simvastatin, atorvastatin):** Ticagrelor is a moderate inhibitor of CYP3A4. Avoid coadministration or use lower doses of simvastatin or atorvastatin.
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase ticagrelor exposure; coadministration is not recommended.
* **Strong CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease ticagrelor exposure; coadministration is not recommended.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Use with caution and monitor closely.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding.
* **Heart Rate:** Be aware of potential for bradycardia, especially in patients with predisposing factors.
## Clinical Pearls
* Ticagrelor has a rapid onset and offset of action, allowing for easier management of bleeding or procedural needs compared to clopidogrel.
* Dyspnea is a common side effect and may necessitate discontinuation, but it is generally transient and not associated with significant pulmonary compromise.
* The 60 mg twice daily dose is indicated for long-term secondary prevention in patients with a history of MI and high risk for recurrent events, typically after at least 12 months on higher-dose dual antiplatelet therapy.
* Ticagrelor should be continued for at least 12 months in ACS patients unless contraindicated.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols before making clinical decisions.*
